?
Orloff John J
EVP, Research & Development
Alexion Pharmaceuticals, Inc.
US, Boston [HQ]
CIK
1643941
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
117,010
Price per Share :
$182.50
Equivalence :
$21,354,325.00
Transaction History
-
A117,010 Shares After TransactionValue : $n/a$0.0Transaction Date : 07/14/21
-
Footnotes
-
-
Footnotes:#1 On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan.#2 On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan.
-
A146,511 Shares After TransactionValue : $n/a$0.0Transaction Date : 07/14/21
-
Footnotes
-
-
Footnotes:#1 On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan.#2 On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan.
-
A88,324 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/28/21
-
Footnotes
-
-
Footnotes:#1 Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date.
-
D0.0 Shares After TransactionValue : $n/a$0.0Transaction Date : 07/21/21
-
Footnotes
-
-
Footnotes:#1 Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
-
F86,367 Shares After TransactionValue : $15,286,959.00$346,389.00Transaction Date : 06/08/21
-
Footnotes
-
-
Footnotes:#1 This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.